### Guideline Page and Request

**SCC-6**

**External Request:** Sanofi/Regeneron Pharmaceuticals request consideration of cemiplimab as the preferred systemic treatment option for the management of patients with advanced cutaneous squamous cell carcinoma.

**Panel Discussion/References**

Based on a review of data and discussion, the panel consensus was to not make changes to the current recommendations because cemiplimab had not been approved by the FDA for any indication.


**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>20</td>
<td>0</td>
<td>7</td>
</tr>
</tbody>
</table>